TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19300423

Group type: EXPERIMENTAL
Intervention: 4.5 g/day CLA with 37.5 mg/day ramipril
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo with 37.5 mg/day ramipril
Number of subjects: 80
Study: 17201808

Group type: EXPERIMENTAL
Intervention: Orlistat treatment for 6 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 29
Study: 15156547

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 11672759

Group type: EXPERIMENTAL
Intervention: 100 mg intravenous acetylsalicylic acid (ASA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9442990

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry in hemiplegic patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry in normal subjects
Number of subjects: 25
Study: 7946163

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 61
Study: 3364865

Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 49

Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 49
Study: 29965890

Group type: EXPERIMENTAL
Intervention: 5-FU
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 26183588

Group type: EXPERIMENTAL
Intervention: Perception of biopsychosocial message
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Not perceiving the biopsychosocial message
Number of subjects: 281

Group type: COMPARATOR
Intervention: Physical therapists' treatment orientations or attitudes
Number of subjects: 281
Study: 25424931

Group type: EXPERIMENTAL
Intervention: Vaccine recipients
Number of subjects: 5673

Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 5673

Group type: EXPERIMENTAL
Intervention: Vaccine recipients (large-scale cohort)
Number of subjects: 5673
Study: 23512639

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) alone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) + venlafaxine extended-release (VXR)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Lisdexamfetamine dimesylate (LDX) or LDX + venlafaxine extended-release (VXR)
Number of subjects: 77
Study: 20518254

Group type: EXPERIMENTAL
Intervention: MAK (1.5 g/day) for 12 months
Number of subjects: 123

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 123
Study: 18389985

Group type: EXPERIMENTAL
Intervention: 2 cm limited quadriceps exposure minimally invasive surgery total knee replacement (2cm Quad MIS TKR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional total knee replacement
Number of subjects: 40
Study: 15971460

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg/day
Number of subjects: 300

Group type: COMPARATOR
Intervention: No beta-blocker (control)
Number of subjects: 300
Study: 12412571

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for Helicobacter pylori eradication
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 10613553

Group type: COMPARATOR
Intervention: Conventional technique (median sternotomy, cardiopulmonary bypass)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass with median sternotomy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lateral minithoracotomy and cardiopulmonary bypass
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Off-pump procedure and lateral minithoracotomy
Number of subjects: 36
Study: 8697983

Group type: EXPERIMENTAL
Intervention: CT-surgery-CT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CT-RT-CT
Number of subjects: 80

Group type: COMPARATOR
Intervention: RT-CT
Number of subjects: 80
Study: 1827125

Group type: EXPERIMENTAL
Intervention: 100 mg/day spironolactone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 100 mg/day CPA
Number of subjects: 48
Study: 6261782

Group type: EXPERIMENTAL
Intervention: 4 mg oral salbutamol
Number of subjects: 25

Group type: COMPARATOR
Intervention: No salbutamol (control)
Number of subjects: 25
Study: 28441894

Group type: EXPERIMENTAL
Intervention: Multiple sclerosis home automated tele-management system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine home rehabilitation (Control)
Number of subjects: 24
Study: 27822319

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (800 mg DHA/day)
Number of subjects: 991

Group type: COMPARATOR
Intervention: Placebo supplements
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil
Number of subjects: 991
Study: 24754630

Group type: EXPERIMENTAL
Intervention: Downhill Walking (DW) at -20%, 1.36 m/s
Number of subjects: 32

Group type: COMPARATOR
Intervention: Level Walking at 0%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Uphill Walking at +20%
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mixed Walking at +20% and -20%
Number of subjects: 32
Study: 23565744

Group type: EXPERIMENTAL
Intervention: High-salience target in working memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-salience target in working memory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very high-salience, 'pop-out' targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory-based effects
Number of subjects: 0
Study: 20236173

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS contralateral to symptoms
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 25 Hz rTMS contralateral to symptoms
Number of subjects: 62

Group type: COMPARATOR
Intervention: 1 Hz rTMS ipsilateral to symptoms
Number of subjects: 62

Group type: COMPARATOR
Intervention: 25 Hz rTMS ipsilateral to symptoms
Number of subjects: 62

Group type: COMPARATOR
Intervention: Left side rTMS
Number of subjects: 62
Study: 19049481

Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg three times daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16638321

Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 40
Study: 12936920

Group type: EXPERIMENTAL
Intervention: Test meal + 0.5 g alcohol/kg body wt (M+A)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Test meal (M)
Number of subjects: 14
Study: 10762288

Group type: EXPERIMENTAL
Intervention: Low dose GH therapy (1 U (0.5 mg) subcutaneously per day, n = 5)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High dose GH therapy (2 U daily, n = 5)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GH therapy after placebo (n = 5)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continued GH replacement (n = 9)
Number of subjects: 16
Study: 8817982

Group type: EXPERIMENTAL
Intervention: Centrifugal pump (Lifestream; St. Jude Medical)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Centrifugal pump (BP‐80; Medtronic)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Roller pump (Mera Co.)
Number of subjects: 29
Study: 1597852

Group type: EXPERIMENTAL
Intervention: Regular coffee
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Purified caffeine (200 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (highly decaffeinated coffee for regular coffee and china bitter extract for caffeine)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Regular coffee in habitual coffee drinkers (5 cups/day)
Number of subjects: 15
Study: 4012507

Group type: EXPERIMENTAL
Intervention: Mycoplasma pneumoniae
Number of subjects: 39

Group type: COMPARATOR
Intervention: Matched comparative group
Number of subjects: 39
Study: 31206607

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg rabbit anti-thymocyte globulin (ATG) for 5 days
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: 3.5 mg/kg rabbit anti-thymocyte globulin (ATG) for 5 days
Number of subjects: 222
Study: 30308402

Group type: EXPERIMENTAL
Intervention: Marsupialization
Number of subjects: 134

Group type: COMPARATOR
Intervention: Gland Excision
Number of subjects: 134
Study: 26843138

Group type: EXPERIMENTAL
Intervention: Dedicated Dietitian (DD) protocol
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control protocol
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Trained Hospital Dietitian (THD) protocol
Number of subjects: 394
Study: 1375678

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study: 22868187

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 0
Study: 20523078

Group type: EXPERIMENTAL
Intervention: Oral risperidone orodispersible tablet
Number of subjects: 124

Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 124
Study: 18670740

Group type: EXPERIMENTAL
Intervention: Irbesartan (150-300 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Quinapril (20-40 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study: 16440578

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream applied once daily
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream applied twice daily
Number of subjects: 13
Study: 12790211

Group type: EXPERIMENTAL
Intervention: Continuous Group (nitrous oxide 67% and oxygen 33% for 6 h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Discontinuous Group (nitrous oxide for 3 h, then oxygen)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control Group (nitrous oxide 67% and oxygen 33% for 6 h)
Number of subjects: 16
Study: 10535248

Group type: EXPERIMENTAL
Intervention: HIV (+) patients with SD
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: HIV (‐) patients with SD
Number of subjects: 129

Group type: COMPARATOR
Intervention: HIV (+) patients without SD
Number of subjects: 129

Group type: COMPARATOR
Intervention: HIV (‐) patients without SD
Number of subjects: 129
Study: 8889909

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-150 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fluoxetine (20-80 mg/day)
Number of subjects: 100
Study: 1380148

Group type: EXPERIMENTAL
Intervention: CODE chemotherapy with recombinant human granulocyte colony-stimulating factor
Number of subjects: 0

Group type: COMPARATOR
Intervention: CODE chemotherapy without recombinant human granulocyte colony-stimulating factor
Number of subjects: 0
Study: 3880597

Group type: EXPERIMENTAL
Intervention: 0.22‐micron IVEX‐HP filters
Number of subjects: 541

Group type: COMPARATOR
Intervention: No filters
Number of subjects: 541
Study: 31200465

Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC) consisting of four cycles of five minutes followed by five minutes of reperfusion before IRI.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ischemia-Reperfusion Injury (IRI) consisting of twenty minutes followed by 15 minutes of reperfusion.
Number of subjects: 19
Study: 29505471

Group type: EXPERIMENTAL
Intervention: GSK561679 (CRHR1 antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27178257

Group type: EXPERIMENTAL
Intervention: DAGR 1 mg QD
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: DAGR 5 mg QD
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: DAGR 10 mg QD
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: DAGR 15 mg QD
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: DAGR 9 mg QD
Number of subjects: 323

Group type: COMPARATOR
Intervention: Prednisone 5 mg QD
Number of subjects: 323

Group type: COMPARATOR
Intervention: Prednisone 10 mg QD
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo QD
Number of subjects: 323
Study: 25293764

Group type: EXPERIMENTAL
Intervention: Probiotic yogurt containing 10(10) CFU Lactobacillus rhamnosus GR‐1 per 250 g
Number of subjects: 104

Group type: COMPARATOR
Intervention: Whole milk or no intervention (control)
Number of subjects: 104
Study: 19692197

Group type: EXPERIMENTAL
Intervention: High information provision
Number of subjects: 320

Group type: COMPARATOR
Intervention: Low information provision
Number of subjects: 320
Study: 16385833

Group type: EXPERIMENTAL
Intervention: Single-dose internal brachytherapy (12 Gy)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placement of an Ultraflex stent
Number of subjects: 209
Study: 11979156

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadobenate dimeglumine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9279536

Group type: EXPERIMENTAL
Intervention: acute hyperglycaemic hyperinsulinaemia (HG) with plasma glucose at 15 mmolL‐1
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: euglycaemic hyperinsulinaemia (HI) with plasma insulin at 80 mUL‐1 and glucose at 4‐5 mmolL‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: i.v. saline (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: acute hyperglycaemic hyperinsulinaemia (HG)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: euglycaemic hyperinsulinaemia (HI)
Number of subjects: 6
Study: 8166529

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation (HFJV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 9
Study: 3209280

Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg plus Ibopamine 200 mg
Number of subjects: 12
Study: 11556763

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream, applied once daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream
Number of subjects: 0
Study: 31374668

Group type: EXPERIMENTAL
Intervention: Challenge Point Framework (CPF) scheduling
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fixed scheduling
Number of subjects: 23
Study: 29550384

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning (120 mg/m2 fludarabine + 4 doses of 2 Gy total-body irradiation)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Myeloablative conditioning (6 doses of 2 Gy total-body irradiation + 120 mg/kg cyclophosphamide)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning
Number of subjects: 195

Group type: COMPARATOR
Intervention: Myeloablative conditioning
Number of subjects: 195
Study: 26252868

Group type: EXPERIMENTAL
Intervention: Machine learning methods applied to analyze conversations of suicidal adolescents
Number of subjects: 60

Group type: COMPARATOR
Intervention: Matched controls (nonsuicidal adolescents)
Number of subjects: 60
Study: 25154982

Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg or 15 mg/kg plus chemotherapy
Number of subjects: 303
Study: 22702147

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 72

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 72
Study: 20818474

Group type: EXPERIMENTAL
Intervention: BCAAs supplementation (0.4 g/kg/day and 0.2 g/kg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 17362472

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg one inhalation bid plus additional inhalations as needed
Number of subjects: 3335

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 25/125 microg two inhalations bid plus as-needed terbutaline
Number of subjects: 3335

Group type: COMPARATOR
Intervention: Fixed-dose budesonide/formoterol 320/9 microg one inhalation bid plus as-needed terbutaline
Number of subjects: 3335

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol for maintenance and relief
Number of subjects: 3335

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 3335
Study: 15102873

Group type: EXPERIMENTAL
Intervention: Intravenous palonosetron (0.3 to 90 microg/kg)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Intravenous palonosetron
Number of subjects: 112
Study: 11581434

Group type: EXPERIMENTAL
Intervention: Educational video intervention (20-minute video and brochure about antibiotics)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (no video intervention)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Educational video intervention (20-minute video)
Number of subjects: 193
Study: 9704672

Group type: EXPERIMENTAL
Intervention: Three-drug combination of docetaxel (75 mg/m2), ifosfamide (3,000 mg/m2), and cisplatin (75 mg/m2) with lenograstim support
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Three-drug combination of docetaxel, ifosfamide, and cisplatin
Number of subjects: 12
Study: 7991433

Group type: EXPERIMENTAL
Intervention: Iron supplementation with iron sulfate 5 mg/kg until day 56
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 17
Study: 2567483

Group type: EXPERIMENTAL
Intervention: Sotalol (320 mg.d‐1)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg.d‐1)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg.d‐1)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 74
Study: 5124439

Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 100 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 75 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 50 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 20 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 15 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pyrantel embonate 10 mg/kg
Number of subjects: 60
Study: 30701726

Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging (HSI)
Number of subjects: 32
Study: 28627029

Group type: EXPERIMENTAL
Intervention: Test cream (moisturizer containing urea, glycerine, and petrolatum)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 26742399

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Thoracic Paravertebral Block (TPVB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epidural Analgesia
Number of subjects: 12
Study: 23792400

Group type: EXPERIMENTAL
Intervention: Four bar-connected implants
Number of subjects: 49

Group type: COMPARATOR
Intervention: Six bar-connected implants
Number of subjects: 49
Study: 22013797

Group type: EXPERIMENTAL
Intervention: Reduning Injection (RI)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of Reduning Injection with Ribavirin Injection or antibiotics
Number of subjects: 76

Group type: COMPARATOR
Intervention: Western medicine (WM)
Number of subjects: 76
Study: 18440201

Group type: EXPERIMENTAL
Intervention: dobutamine (5‐40 mug/kg/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: levosimendan (24 mug/kg in 10 minutes)
Number of subjects: 30
Study: 16945029

Group type: EXPERIMENTAL
Intervention: Brushing with dentifrice
Number of subjects: 120

Group type: COMPARATOR
Intervention: Brushing without dentifrice
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Different types of dentifrice
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Order of brushing procedure
Number of subjects: 120
Study: 15072892

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (gonadotropin‐releasing hormone agonist or bilateral orchiectomy)
Number of subjects: 79
Study: 11424777

Group type: EXPERIMENTAL
Intervention: Meperidine 75 mg i.m.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg i.m.
Number of subjects: 40
Study: 9105521

Group type: EXPERIMENTAL
Intervention: High-dose immunotherapy (HDI) group (MTD >= 4 micrograms Der p 1)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional immunotherapy (CI) group (MTD < 4 micrograms Der p 1)
Number of subjects: 43
Study: 8394858

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir, 5 mg/kg twice daily for 14 days followed by 5 mg/kg once daily for 14 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Deferred treatment (control)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 35
Study: 2941267

Group type: EXPERIMENTAL
Intervention: Stepped care antihypertensive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazide treated patients
Number of subjects: 0
Study: 29983748

Group type: EXPERIMENTAL
Intervention: Metatarsal pad condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Anatomically-based masking protocol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional masking protocol
Number of subjects: 36
Study: 27684835

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study: 24909530

Group type: EXPERIMENTAL
Intervention: Online testable pathogenesis maps
Number of subjects: 65

Group type: COMPARATOR
Intervention: Existing online resources
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pathogenesis maps (both groups)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pathogenesis maps
Number of subjects: 65
Study: 23039014

Group type: EXPERIMENTAL
Intervention: Garlic tablets (2 tablets daily for 1 month)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo tablets (2 tablets daily for 1 month)
Number of subjects: 44
Study: 20127873

Group type: EXPERIMENTAL
Intervention: High alexithymia
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low alexithymia
Number of subjects: 34
Study: 18353996

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg b.i.d.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg b.i.d.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15741708

Group type: EXPERIMENTAL
Intervention: Personalized-form (PF) letter messages
Number of subjects: 1574

Group type: EXPERIMENTAL
Intervention: Personalized-tailored (PT) letter messages
Number of subjects: 1574

Group type: COMPARATOR
Intervention: Control (no letter)
Number of subjects: 1574
Study: 12218522

Group type: EXPERIMENTAL
Intervention: Gertie Marx needle (127 mm long)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sprotte needle (120 mm long)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 73
Study: 10064669

Group type: EXPERIMENTAL
Intervention: TTS-fentanyl (transdermal fentanyl system)
Number of subjects: 11
Study: 7586783

Group type: EXPERIMENTAL
Intervention: Azapropazone (APZ) 300 mg t.i.d. for three weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63